Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ventyx Biosciences, Inc.

1.13
+0.06005.61%
Post-market: 1.130.00000.00%17:54 EDT
Volume:901.09K
Turnover:1.03M
Market Cap:80.38M
PE:-0.57
High:1.19
Open:1.08
Low:1.06
Close:1.07
Loading ...

Company Profile

Company Name:
Ventyx Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
81
Office Location:
12790 El Camino Real,Suite 200,San Diego,California,United States
Zip Code:
92130
Fax:
- -
Introduction:
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Directors

Name
Position
Raju S. Mohan
Chief Executive Officer and Director
Sheila Gujrathi
Chair of the Board
Aaron Royston
Director
Jigar R. Choksey
Director
Richard S. Gaster
Director
Somasundaram Subramaniam
Director
William White
Director

Shareholders

Name
Position
Raju S. Mohan
Chief Executive Officer and Director
Martin D. Auster
Chief Financial Officer
Christopher W. Krueger
Chief Business Officer
John M. Nuss
Chief Scientific Officer
Jorn Drappa
Chief Medical Officer